Oncology

Latest News

Value-based care. | Image Credit: irissca - stock.adobe.com
Legal Navigation Services Key to Addressing Disparities in Cancer Care

July 31st 2025

A significant number of patients with cancer, caregivers, and health care professionals face significant disparities in legal issues, with the most common needs revolving around health insurance, finances, employment, and disability insurance.

Radiotherapy can work synergistically with immunotherapy by reprogramming the tumor microenvironment. | Image credit: Crystallight-stock.adobe.com
Brain Radiotherapy Plus ICIs Boost Survival in SCLC With Brain Metastases

July 30th 2025

As SCLC continues to pose a therapeutic challenge due to rapid progression and early metastasis, the convergence of immunotherapy and precision radiation holds promise to extend survival and improve outcomes. | Image credit: mi_viri - stock.adobe.com
Chemoimmunotherapy Shows Promise for Limited-Stage SCLC in Real-World Study

July 29th 2025

The findings suggest that inhibition of midkine might be a meaningful tool to improve treatment outcomes in SCLC. | Image credit: Pixel-Shot - stock.adobe.com
Midkine May Play Key Role in SCLC

July 24th 2025

The FDA has issued a complete response letter for RP1 plus nivolumab for advanced melanoma after a PD-1 inhibitor–containing regimen. | Image credit: ra2studio - stock.adobe.com
RP1 Plus Nivolumab Receives CRL for Advanced Melanoma

July 24th 2025

Join this expert panel to discuss precision medicine in NSCLC, current immunotherapies, and more.

Watch the series now!

Join a panel of leaders as they discuss treatment for patients diagnosed with metastatic NSCLC without driver mutations
Continuing Medical Education
View All
August 3rd 2025

The Economics of Transthyretin-Mediated Amyloidosis: Balancing Equity and Access in Resource Allocation

1 Credit / Cardiology, Neurology
August 3rd 2025

Advancing Immunotherapy in Endometrial Cancer: A Managed Care Perspective on Personalized Care

1.5 Credits / Gynecologic Cancer, Health Equity, Diversity & Inclusion, Oncology, Women's Health

More News

This Week in Managed Care: November 10, 2017
November 10th 2017

This Week in Managed Care: November 10, 2017

This week, the top managed care stories included a vote in Maine to expand Medicaid and other election day 2017 results; CMS issued final rules for the DIabetes Prevention Program; and a report from the American Society of Clinical Oncology highlighted the link between alcohol consumption and cancer.
Mutation May Be Associated With Resistance to NSCLC Immunotherapy
November 8th 2017

Mutation May Be Associated With Resistance to NSCLC Immunotherapy

Smita Jaggernauth, PharmD
A specific mutation has been linked with acquired resistance in immunotherapy drugs used to treat non–small lung cancer (NSCLC).
The American Journal of Managed Care® Announces Dr Michael Kolodziej as the Keynote Speaker for the Patient-Centered Oncology Care® Meeting
November 8th 2017

The American Journal of Managed Care® Announces Dr Michael Kolodziej as the Keynote Speaker for the Patient-Centered Oncology Care® Meeting

Leading healthcare innovation officer to share information about digital health, managed services, and provider sectors in the healthcare arena.
Tesh Khullar: Community Oncologists Need to Understand Impact of Biosimilars on Their Business
November 8th 2017

Tesh Khullar: Community Oncologists Need to Understand Impact of Biosimilars on Their Business

Biosimilars for core therapeutics in cancer are starting to come out, and community oncologists need to understand what that means for their business, as well as what proposed policy changes could mean for reimbursement, explained Tesh Khullar,
Roche Gets Drug Approvals for First Treatment for a Rare Blood Disorder and NSCLC
November 8th 2017

Roche Gets Drug Approvals for First Treatment for a Rare Blood Disorder and NSCLC

AJMC Staff
Roche had 2 drugs approved by the FDA—one that is the first approved treatment for a rare blood disease and the other is approved as a first-line treatment for anaplastic lymphoma kinase-positive metastatic non–small cell lung cancer.
ASCO: Alcohol Linked to Several Types of Cancer
November 8th 2017

ASCO: Alcohol Linked to Several Types of Cancer

Jaime Rosenberg
According to evidence gathered by the American Society of Clinical Oncology (ASCO), alcohol consumption is linked with an increased risk of cancer and can negatively impact cancer treatment.
Study to Explore Link Between Diabetes, Pancreatic Cancer
November 7th 2017

Study to Explore Link Between Diabetes, Pancreatic Cancer

Mary Caffrey
Rising rates of diabetes and obesity have been cited in the fact that pancreatic cancer is expected to be the second-leading cause of cancer death by 2020.
Incidence Rates of Early-Stage Breast and Colorectal Cancer Increased Following Enactment of ACA
November 7th 2017

Incidence Rates of Early-Stage Breast and Colorectal Cancer Increased Following Enactment of ACA

Jaime Rosenberg
With the ACA putting emphasis on preventive care, there has been an immediate increase in breast and coloreactal cancer screenings. A recent study found that incidence rates of early-stage breast and colorectal cancer increased in 2014, but did not vary for late-stage breast and colorectal cancer.
3D Mammograms and Breath Test Represent Advances in Breast Cancer Detection Technology
November 5th 2017

3D Mammograms and Breath Test Represent Advances in Breast Cancer Detection Technology

Alison Rodriguez
Recent advancements in technology, specifically in detection methods, have demonstrated significant improvement in how early patients are diagnosed with breast cancer and treated.
Managing Neutropenia Toxicity With CDK 4/6 Inhibitors Used to Treat Metastatic Breast Cancer
November 4th 2017

Managing Neutropenia Toxicity With CDK 4/6 Inhibitors Used to Treat Metastatic Breast Cancer

Laura Joszt, MA
In a pair of interviews, experts discuss neutropenia resulting from treatment of metastatic breast cancer with CDK4/6 inhibitors.
This Week in Managed Care: November 3, 2017
November 3rd 2017

This Week in Managed Care: November 3, 2017

AJMC Staff
This week, the top managed care news included the first day of open enrollment; data from CMS that indicate the progress accountable care organizations are making; and findings that most people with obesity aren't get screened for it or getting care.
Fiber Intake Associated With Lower Mortality in Patients with Colorectal Cancer
November 3rd 2017

Fiber Intake Associated With Lower Mortality in Patients with Colorectal Cancer

Jaime Rosenberg
Increased fiber, especially from cereal, intake after the diagnosis of non-metastatic colorectal cancer (CRC) is associated with lower CRC-specific and overall mortality.
FDA Approves New Treatment for Adults With Mantle Cell Lymphoma
November 1st 2017

FDA Approves New Treatment for Adults With Mantle Cell Lymphoma

Jaime Rosenberg
Mantle cell lymphoma is an aggressive type of non-Hodgkin lymphoma. Acalabrutinib (Calquence) is a kinase inhibitor that works by blocking an enzyme the cancer needs to multiply and spread.
FDA Grants Priority Review for Lilly's Verzenio for Metastatic Breast Cancer
November 1st 2017

FDA Grants Priority Review for Lilly's Verzenio for Metastatic Breast Cancer

Alison Rodriguez
The FDA has granted Priority Review designation for Eli Lilly and Company’s New Drug Application (NDA) for Verzenio (abemaciclib), a cyclindependent kinase 4 and 6 inhibitor for metastatic breast cancer. The decision was based on the MONARCH 3 study, which examined abemaciclib as an initial endocrine-based therapy.
Evidence-Based OncologyTM Highlights Role of Pharmacist in Cancer Care
November 1st 2017

Evidence-Based OncologyTM Highlights Role of Pharmacist in Cancer Care

As cancer care becomes more expensive and complex, the role of the pharmacist is expanding, from managing the shift to greater use of oral therapies to navigating the revenue cycle, as explored in the new issue of Evidence-Based Oncology™, a publication of The American Journal of Managed Care.®
Educating Patients About Risk of Febrile Neutropenia Associated With Strong Chemotherapy
October 31st 2017

Educating Patients About Risk of Febrile Neutropenia Associated With Strong Chemotherapy

AJMC Staff
Strong chemotherapy may be part of the treatment plan for patients diagnosed with cancer, but it also comes with risks. A new campaign will empower patients with cancer to better understand and navigate risks such as febrile neutropenia that are associated with strong chemotherapy.
70-GS Influences Physician Treatment Guidance for Patients With Early Breast Cancer
October 31st 2017

70-GS Influences Physician Treatment Guidance for Patients With Early Breast Cancer

Jaime Rosenberg
Results of the 70-gene signature assay strongly influence physician's treatment recomendations for patients with early breast cancer who were classified as intermediate risk by the 21-gene assay.
Site Logo
October 30th 2017

Data Challenges Under the Oncology Care Model

Darcie Hurteau
An overview of factors that make the Oncology Care Model performance period data challenging to navigate and use.
Global Cancer Burden in Young Adults Differs From That in Other Age Groups
October 30th 2017

Global Cancer Burden in Young Adults Differs From That in Other Age Groups

Jaime Rosenberg
A new study found that the global cancer burden in young adults differs from that in younger and older age groups and was more common in women.
ARROW Trial: Multiple Myeloma Patients Have Longer PFS With Kyprolis Once-Weekly Regimen
October 29th 2017

ARROW Trial: Multiple Myeloma Patients Have Longer PFS With Kyprolis Once-Weekly Regimen

Alison Rodriguez
Results of the Phase 3 ARROW trial revealed that patiehts with refractory multiple myeloma can live up to 3.6 months longer, without their disease worsening, when Kyprolis (carfilzomib) is administered once-weekly at the 70 mg/m2 dose with dexamethasone rather than Kyprolis administered twice-weekly at the 27 mg/m2 dose with dexamethasone, according to Amgen.
Study Finds Association Between PARPis Treatment and Severe Hematologic Toxicities
October 28th 2017

Study Finds Association Between PARPis Treatment and Severe Hematologic Toxicities

Alison Rodriguez
Study Finds Need for Standardization of Immune Checkpoint Inhibitor Assays in NSCLC
October 28th 2017

Study Finds Need for Standardization of Immune Checkpoint Inhibitor Assays in NSCLC

Alison Rodriguez
Site Logo
October 27th 2017

Expanding Options for Individualized Treatment of Advanced NSCLC

Christina Mattina
James R. Jett, MD, gave an overview of the advances in diagnosis and treatment of non–small cell lung cancer (NSCLC) during a session at the National Association of Managed Care Physicians Fall Managed Care Forum 2017.
Childhood Cancer Survivors Face Job Lock to Keep Insurance Coverage
October 27th 2017

Childhood Cancer Survivors Face Job Lock to Keep Insurance Coverage

Alison Rodriguez
Many of survivors of childhood cancer who are now within the prime age for labor force participation are reluctant to make changes in their employment because of access to health insurance, and therefore, job lock is common among this population.
Site Logo
October 26th 2017

Survey: Americans Have High Concerns About Cancer, Low Awareness of Risk Factors

Kelly Davio
Results of the first annual National Cancer Opinion Survey, established by the American Society of Clinical Oncology (ASCO), show that the majority of Americans are unaware of several key risk factors for cancer, and that a minority are taking active steps to reduce their personal risk.
Site Logo
October 25th 2017

Stakeholders Weigh-in on Payment Reform in Cancer Care

Surabhi Dangi-Garimella, PhD
Tuple Health, a healthcare technology startup, interviewed some of the stakeholders participating in value-based care delivery and OCM, to gain their perspective of the state of cancer care and healthcare reform. The results were presented at the Community Oncology Alliance Payer Exchange Summit on Oncology Payment Reform.
Site Logo
October 25th 2017

The Commercial Payer OCM Experience: Year 1

Surabhi Dangi-Garimella, PhD
Representatives from 3 payers who partnered with providers on the Oncology Care Model (OCM) took the stage at Community Oncology Alliance (COA)’s Payer Exchange Summit on Oncology Payment Reform to outline their experience with OCM and how it has differed from other care models.
Terrill Jordan: Education and Data Are Key for OCM Success
October 25th 2017

Terrill Jordan: Education and Data Are Key for OCM Success

Education is key to succeed in the Oncology Care Model, but presenting data in a simple format for clinicians to use is also critical, said Terrill Jordan, CEO, of Regional Cancer Care Associates.
Expert Recommendations for Pegfilgrastim in Chemotherapy-Induced Febrile Neutropenia
October 25th 2017

Expert Recommendations for Pegfilgrastim in Chemotherapy-Induced Febrile Neutropenia

Alison Rodriguez
Researchers developed additional guidance for using granulocyte colony-stimulating factors to optimize pegfilgrastim use in clinical practices for patients at risk of chemotherapy-induced febrile neutropenia.
Physicians Need Clearer Metrics Before Taking on 2-Sided Risk
October 25th 2017

Physicians Need Clearer Metrics Before Taking on 2-Sided Risk

Before physicians will be more willing to take on 2-sided risk, there needs to be clearer metrics that the physicians know will be achievable, said Sarah Cevallos, chief revenue cycle officer at Florida Cancer Specialists.
<1
...
646566676869707172
...
187>

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo